Literature DB >> 16749853

Methods to evaluate biliary excretion of drugs in humans: an updated review.

Giulia Ghibellini1, Elaine M Leslie, Kim L R Brouwer.   

Abstract

Determining the biliary clearance of drugs in humans is very challenging because bile is not readily accessible due to the anatomy of the hepatobiliary tract. The collection of bile usually is limited to postsurgical patients with underlying hepatobiliary disease. In healthy subjects, feces typically are used as a surrogate to quantify the amount of drug excreted via nonurinary pathways. Nevertheless, it is very important to characterize hepatobiliary elimination because this is a potential site of drug interactions that might result in significant alterations in systemic or hepatic exposure. In addition to the determination of in vivo biliary clearance values of drugs, the availability of in vitro models that can predict the extent of biliary excretion of drugs in humans may be a powerful tool in the preclinical stages of drug development. In this review, recent advances in the most commonly used in vivo methods to estimate biliary excretion of drugs in humans are outlined. Additionally, in vitro models that can be employed to investigate the molecular processes involved in biliary excretion are discussed to present an updated picture of the new tools and techniques that are available to study the complex processes involved in hepatic drug transport.

Entities:  

Mesh:

Year:  2006        PMID: 16749853      PMCID: PMC2572858          DOI: 10.1021/mp060011k

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  150 in total

Review 1.  Drug transport proteins in the liver.

Authors:  Klaas Nico Faber; Michael Müller; Peter L M Jansen
Journal:  Adv Drug Deliv Rev       Date:  2003-01-21       Impact factor: 15.470

Review 2.  Biliary excretion of antimicrobial drugs.

Authors:  George Karachalios; Konstantinos Charalabopoulos
Journal:  Chemotherapy       Date:  2002       Impact factor: 2.544

Review 3.  Clinical pharmacology of new histamine H1 receptor antagonists.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Authors:  R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

6.  Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats.

Authors:  X Liu; J P Chism; E L LeCluyse; K R Brouwer; K L Brouwer
Journal:  Drug Metab Dispos       Date:  1999-06       Impact factor: 3.922

7.  Optimization of culture conditions for determining hepatobiliary disposition of taurocholate in sandwich-cultured rat hepatocytes.

Authors:  P Chandra; E L Lecluyse; K L Brouwer
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-06       Impact factor: 2.416

8.  Disposition of methadone in methadone maintenance.

Authors:  E Anggård; L M Gunne; J Homstrand; R E McMahon; C G Sandberg; H R Sullivan
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

9.  Penetration of ciprofloxacin and fleroxacin into biliary tract.

Authors:  C E Edmiston; E C Suarez; A P Walker; M P Demeure; C T Frantzides; W J Schulte; S D Wilson
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Biliary and renal excretion of paracetamol in man.

Authors:  C P Siegers; W Loeser; J Gieselmann; D Oltmanns
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

View more
  26 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 2.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

3.  Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.

Authors:  Jackie C Bloomer; Mike Nash; Alison Webb; Bruce E Miller; Aili L Lazaar; Claire Beaumont; William J Guiney
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

4.  Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.

Authors:  Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

Review 5.  A perspective on efflux transport proteins in the liver.

Authors:  K Köck; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2012-09-05       Impact factor: 6.875

6.  Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor.

Authors:  Lin-Zhi Chen; John P Sabo; Elsy Philip; Lois Rowland; Yan Mao; Bachir Latli; Diane Ramsden; Debra A Mandarino; Rucha S Sane
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

7.  Use of Entero-Test, a simple approach for non-invasive clinical evaluation of the biliary disposition of drugs.

Authors:  William J Guiney; Claire Beaumont; Steve R Thomas; Darren C Robertson; Simon M McHugh; Annelize Koch; Duncan Richards
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

8.  Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches.

Authors:  Claire Beaumont; Graeme C Young; Tom Cavalier; Malcolm A Young
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

9.  Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Authors:  Brian F Kiesel; Robert A Parise; Jianxia Guo; Donna M Huryn; Paul A Johnston; Raffaele Colombo; Malabika Sen; Jennifer R Grandis; Jan H Beumer; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-24       Impact factor: 3.333

10.  Predicting when biliary excretion of parent drug is a major route of elimination in humans.

Authors:  Chelsea M Hosey; Fabio Broccatelli; Leslie Z Benet
Journal:  AAPS J       Date:  2014-07-09       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.